Stock Region Penny Picks
🚀 Walmart Wins, AI Pivots, and a Chapter 11 Warning
🚀 Walmart Wins, AI Pivots, and a Chapter 11 Warning
The stocks featured in this report were previously delivered in our trading room in real-time. To access Stock Region’s real-time trade ideas, then be sure to purchase a membership now.
DISCLAIMER: The following content is for informational and entertainment purposes only. Stock Region is not a registered investment advisor, and nothing in this newsletter constitutes financial advice, trading recommendations, or solicitation to buy or sell any securities. The stock market is volatile and risky. Always do your own due diligence and consult with a certified financial professional before making any investment decisions. You are responsible for your own trades.
📋 What’s Inside This Edition
The Big Winners: Retail distribution and massive earnings beats.
The AI Pivot Parade: Everyone is building data centers (and we mean everyone).
Biotech Breakdown: FDA approvals, obesity drugs, and heart therapies.
The Danger Zone: A household name files Chapter 11 (and shareholders get nothing).
The Watchlist: Tickers on the move.
Is it just me, or did the market just chug a double espresso this week? We’ve seen everything from massive retail deals to the grim reality of bankruptcy court in the span of about 72 hours.
It feels like we are in two different markets right now. On one side, you have companies pivoting hard to AI and raking in infrastructure contracts. On the other, legacy tech hardware is struggling to stay afloat. It’s a wild time to be a trader.
Let’s cut through the noise and look at what actually matters.
🛍️ Retail & Revenue: The “Real World” Wins
$AXIL (AXIL Brands)
They just landed a National Retail Distribution Agreement with Walmart.
My Take: This is the holy grail for any consumer product. Getting on Walmart shelves isn’t just a revenue booster; it’s a validation stamp. If execution goes smooth, volume should follow. Keep a close eye on their next quarterly report to see the impact.
$ZDGE (Zedge)
Quarterly earnings of $0.07 per share, beating estimates by a whopping 250%.
My Take: A beat is a beat, but a 250% beat? That’s a mispricing by the analysts. Markets love surprises, and this is the good kind.
$RILY (B. Riley Financial)
Reported earnings of $4.50/share (vs a loss last year).
My Take: That is a massive turnaround. Going from a loss to $4.50 EPS is the kind of volatility that creates aggressive repricing. If this is a trend and not a one-off, the shorts might be in trouble.
🤖 The AI & Infrastructure Rush
I’m seeing a trend here, folks. If you aren’t building a data center or buying chips, are you even a public company in 2025?
$SOPA (Society Pass): Pivoting to invest in AI-driven data centers. Opinion: Standard playbook these days, but let’s see the capital allocation.
$GIBO & $MASK: Both announcing massive data center/compute projects ($MASK in Finland, $GIBO in Malaysia). Opinion: The infrastructure build-out is real. The demand for compute power is insatiable right now.
$NAMI (Namibox): Unveiling AI-powered learning glasses. Opinion: Hardware is notoriously hard (see iRobot below), but education tech is ripe for disruption.
🧬 Biotech: High Risk, High Reward
The FDA has been busy, and so have the clinical trials. Here is the pulse:
$CRBP (Corbus): Their obesity pill (CRB-913) is showing weight loss and safety. Opinion: The obesity market is the new gold rush. If they can compete with the big pharma injections using a pill, this is huge.
$BCRX (BioCryst): FDA Approval for ORLADEYO in kids. Opinion: Expanding the label to pediatrics expands the total addressable market. Solid win.
$RADX (Radiopharm): 92% primary endpoint achievement in brain metastases. Opinion: 92% is a number you rarely see in oncology. Very promising.
$IRBT (iRobot) - 💀 The Cautionary Tale:
iRobot enters Chapter 11 with no recovery for common stock holders.The Harsh Reality: This hurts. The makers of Roomba were once tech darlings. This is a brutal reminder that “buying the dip” on a distressed company can sometimes result in a total zero. If you are holding common stock, it’s likely game over.
🔮 The Short Squeeze Watch
$OCG
We saw it over $4.00, then dipping.
Trader’s Note: Shorts hate paying weekend fees. If this thing holds support, it could get spicy. Volatility is the name of the game here.
This week taught us that agility is key. We have $KPLT merging, $QIPT getting acquired (always nice to see an exit), and $VVPR doing some wild joint venture to hold Ripple (XRP) shares.
The market is rewarding innovation (AI/Biotech) and punishing stagnation ($IRBT). Stay liquid, stay skeptical, and don’t fall in love with your positions.
Stay Green,
Stock Region Admin
DISCLAIMER: Investing in stocks, especially small-cap and biotech securities, involves a high degree of risk. You could lose some or all of your investment. The opinions expressed in this newsletter are those of the author and do not necessarily reflect the views of Stock Region as an entity. Past performance is not